Overview
What is Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?
The Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel is a non-profit corporation, founded and managed by leading academic, medical, and research institutions - Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College. Dedicated to improving health and advancing the diagnosis, prevention, and treatment of diseases, the Institute focuses on translational research, generating proof-of-concept studies, and enhancing the scientific activities of the controlling institutions' faculty, fellows, and students within the realms of translational research, chemistry, pharmacology, and drug discovery. The Institute, with a workforce of around 40 employees, is based in New York City and is committed to developing therapeutics that arise from discoveries made in basic science labs, with a current emphasis on Alzheimer's disease, sickle cell, osteoporosis, lysosomal, lipid deposits, Parkinson's, and basal cell carcinoma.
Official website here: www.tritdi.org
Is Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel legitimate?
Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel is a legitimate nonprofit organization registered as a 501(c)(3) entity. Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $568,459
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
Official website here: www.tritdi.org
What is the mission statement of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?
The Sanders Tri-Institutional Therapeutics Discovery Institute is a non-profit organization controlled by leading academic, medical, and research institutions: Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College. Its mission is to enhance health and advance the diagnosis, prevention, and treatment of diseases by fostering and improving translational research, generating innovative proof-of-concept studies, and progressing the scientific activities of the controlling institutions' faculty, fellows, and students in aspects of translational research, chemistry, pharmacology, and drug discovery.
Official website here: www.tritdi.org
Who is the CEO of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?
Peter T Meinkephd is the Principal Officer of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel.
Official website here: www.tritdi.org
What is the revenue of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?
Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel's revenue in 2022 was $17,034,275.
Official website here: www.tritdi.org
Who are the executives of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel and what are their salaries?
The average compensation at Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel during 2022 was $13,865. There are 41 employees at Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel.
Here are 17 key members and their salaries:
- Craig B Thompson Md (Member Of The Board Of Dir) [Trustee/Director]
- Augustine Mk Choi Md (Member Of The Board Of Dir) [Trustee/Director]
- Richard P Lifton Mdphd (Member Of The Board Of Dir) [Trustee/Director]
- Barbara Hempstead Md (Member Of The Board Of Dir) [Trustee/Director]
- Barry Coller Md (Member Of The Board Of Dir) [Trustee/Director]
- David Scheinberg Md Phd (Member Of The Board Of Dir) [Trustee/Director]
- Peter T Meinke Phd (Director)
- Carl Nathan Md (Member Of The Board Of Dir) [Trustee/Director]
- Michael P Vitale (Treasurer - Effective 9/1/22)
- Derek Tan Phd (Member Of The Board Of Dir) [Trustee/Director]
- James H Lapple (Treasurer - 1/1/22-6/30/22)
- Manuel Baca (Vice President,Biologics T)
- Nigel Liverton Phd (Vice President,Chemistry)
- Paul Balderes (Sr. Director)
- Sandra Lorber (Vice President,Finance)
- Patricia Aha (Vice President, Oprations)
- Nathaniel Heintz Phd (Member Of The Board Of Dir) [Trustee/Director]
Official website here: www.tritdi.org
Where can I find the form 990 for Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?
The Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.tritdi.org
Learn more at the official website: www.tritdi.org
Mission Statement of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel
Sanders Tri-Institutional Therapeutics Discovery Institute Inc, a non-profit corporation established by Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College, is dedicated to enhancing health and the diagnosis, prevention, and treatment of diseases. Controlled by these prominent academic, medical, and research institutions, the Institute aims to foster and improve translational research, generate innovative proof-of-concept studies, and advance the scientific activities of the controlling institutions' faculty, fellows, and students in areas of translational research, chemistry, pharmacology, and drug discovery. By nurturing collaborations across the three institutions, the Institute plays a pivotal role in bringing together expertise from various fields to tackle complex health challenges and accelerate the translation of scientific discoveries into clinical applications.
Impact
This information is meant to be a general summary of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
The Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornell plays a crucial role in advancing translational research, drug discovery, and proof-of-concept studies in collaboration with leading academic and research institutions. By focusing on early-stage drug development and providing expertise in medicinal chemistry and compound screening, the institute contributes to the development of therapeutics for diseases such as Alzheimer's, sickle cell anemia, osteoporosis, lysosomal disorders, Parkinson's disease, and basal cell carcinoma. Through its work, the institute aims to improve health outcomes and enhance the diagnosis, prevention, and treatment of various diseases, ultimately making a significant impact on the field of medical research.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
REVENUE FROM COLLABORATION AGREEM
Revenue
$11,911,800
REVENUE FROM AFFILIATION AGREEMEN
Revenue
$5,087,491
Organization Details
Founding Year
2013
Phone
(212) 327-8704
Principal Officer
Peter T Meinkephd
Main Address
1300 YORK AVENUE, NEW YORK, NY, 10065
Website
www.tritdi.org
NTEE Category
Code: H99 - Medical research
If you are a representative of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.